Matching Treatment Options to the Patient: The Role of Botulinum Toxin in Pediatric Patients with Spasticity
Premiere Date: Thursday, June 11, 2020This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, June 11, 2022
Note: Credit Is No Longer Available
 | David M. Simpson, MD, FAAN Professor of Neurology Director, Clinical Neurophysiology and Neuromuscular Division Icahn School of Medicine at Mount Sinai New York, NY |
Spasticity, a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, results from hyper excitability of the stretch reflex. It often causes damage to one or more areas of the central nervous system; therefore, treatment goals should aim to provide symptom relief, ease patient care and decrease caregiver burden, and improve patient function. In order to accomplish these goals, it is imperative that clinicians develop individualized treatment strategies based on shared decision-making, available treatment options, and patient specific factors.
This CMEOCast podcast episode highlights how best to match treatment options with patients, with a specific focus on the safety and efficacy of botulinum toxin as a treatment for patients with spasticity.
At the end of this CE activity, participants should be able to:
- Recognize the clinical manifestations of spasticity.
- Develop individualized treatment strategies based on shared goals, available treatment options and patient-specific factors.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Recognize the clinical manifestations of spasticity.
- Describe individualized treatment strategies based on shared goals, available treatment options and patient-specific factors.
Supported by an educational grant from Allergan.
Physicians, PAs, nurse practitioners, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-100-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Simpson reports that he receives research/grants from Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the advisory committee for Allergan; Ipsen Biopharmaceuticals, Inc; Merz Pharma; and Revance Therapeutics, Inc. He is a consultant for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the speakers bureau for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-022-061120-03
